Petrov N M
Ter Arkh. 1985;57(12):32-6.
A study was made of the antithyroid effect of lithium carbonate in 163 patients with diffuse toxic goiter. In addition to clinical monitoring a radioimmunoassay was used to determine the level of serum thyroxine, triiodothyronine and thyrotropin. The most important indicators of the activities of the cardiovascular system were analysed by RCG and polycardiography findings. Data on a rapid and stable antithyroid effect of lithium carbonate were obtained. With the concentration of lithium ion within 0.4-0.8 meq/l the basal level of thyroxine and triiodothyronine decreased by 40 and 35% respectively. Reducing the level of circulating thyronines in hemocirculation lithium did not cause a sharp rise of blood thyrostimulating activity. In combined application of lithium and mercasolil the thyrostatic effect of both drugs was summarized. Lithium did not block iodine accumulating function of the thyroid permitting, if necessary, its combination with iodine drugs. Possible mechanisms of the effect of lithium on the thyroid in hyperthyroidism and its role in multimodality therapy of the diffuse toxic goiter were discussed.
对163例弥漫性毒性甲状腺肿患者进行了碳酸锂抗甲状腺作用的研究。除临床监测外，还采用放射免疫分析法测定血清甲状腺素、三碘甲状腺原氨酸和促甲状腺激素水平。通过放射性心脑血管造影和多导心电图检查结果分析心血管系统活动的最重要指标。获得了碳酸锂快速、稳定的抗甲状腺作用的数据。当锂离子浓度在0.4 - 0.8毫当量/升时，甲状腺素和三碘甲状腺原氨酸的基础水平分别下降了40%和35%。锂降低血液循环中甲状腺激素水平时，并未引起血液中促甲状腺活性的急剧升高。锂与甲巯咪唑联合应用时，两种药物的甲状腺抑制作用相加。锂并不阻断甲状腺的碘蓄积功能，必要时可使其与碘剂联合使用。讨论了锂对甲状腺功能亢进患者甲状腺作用的可能机制及其在弥漫性毒性甲状腺肿多模式治疗中的作用。
